Abstract: Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.

Abstract: Described herein are novel methods of treating disorders using oral, systemically bioavailable forms of butyrate. Aspects of the disclosure relate to a method for treating a disorder in a subject comprising administering the oral, systemically bioavailable composition to the subject, wherein the disorder is selected from inflammatory bowel disease (IBD), multiple sclerosis (MS), a neuroinflammatory condition, food allergies, rheumatoid arthritis (RA), asthma, celiac disease, non-alcoholic steatohepatitis (NASH), diabetes, Alzheimer's disease (AD), inflammaging, beta-hemoglobinopathies, vascular inflammatory conditions, atopic dermatitis and psoriasis, pulmonary fibrosis, and systemic sclerosis.

Abstract: This disclosure relates to a method for reducing somatic cell count (SCC) in milk of a ruminant lactating animal, for increasing milk fat yield of a ruminant lactating animal, and/or for use in the prevention or treatment of mastitis in a ruminant animal, for increasing fecal consistency of a ruminant animal, for reducing methane production of a ruminant animal. In particular, this disclosure relates to a specified compound for use in the method, and to a nutrition composition for ruminant animals comprising the specified compound.

Abstract: A method for the prevention and treatment of obesity, non-alcoholic fatty liver disease, alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver cirrhosis, liver fibrosis, elevated liver enzyme levels (ALT, AST, ALP), hepatocellular carcinoma, hypercholesterolemia and cardiovascular diseases associated therewith, insulin resistance, impaired glucose tolerance, hyperglycemia, type II diabetes mellitus, and metabolic syndrome. This method involves the inhibition of mARC1 in the patient by chemical compounds (retardants, inhibitors) of the general structure: Inhibitors and retardants refer to all chemical compounds that reduce or downregulate the conversion rate of mARC1. Downregulation in the patient means that a lower conversion rate of reactions catalyzed by mARC1 is achieved in the patient by the inhibitors in a drug. Similarly, protein-protein interactions involving mARC1 are downregulated in the patient by a drug with the described compounds.

Abstract: A method of treating a subject having, or at risk of having, leaky gut caused by sulfate reducing bacteria generally includes administering to the subject an amount of a Snail inhibitor or an inhibitor of sulfate reducing bacteria effective to reduce ameliorate at least one symptom or clinical sign of leaky gut caused by sulfate reducing bacteria. A method of inhibiting deterioration of cellular junctions in cells contacted with sulfate reducing bacteria generally includes contacting the cells with an amount of Snail inhibitor or an inhibitor of sulfate reducing bacteria effective to reduce the extent to which the sulfate reducing bacteria deteriorate cellular junctions compared to untreated cells.

Abstract: An improved method of treatment with cabazitaxel composition that is substantially free of premedication prior to the administration of the cabazitaxel composition to the patient.

Abstract: A therapeutic method for a cat treats chronic kidney disease to inhibit progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat or improve the overall survival rate or the observed survival rate. The therapeutic method for a cat with chronic kidney disease inhibits progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 3 or 4 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) in an amount of 90 to 130 ?g of the compound represented by formula (I) daily: wherein R represents hydrogen or a pharmacologically acceptable cation.

Abstract: Artemisia annua and A. afra dichloromethane extracts contain bactericidal activity against Mycobacterium tuberculosis (Mtb) strain mc26230 under natural infection stress conditions: carbon source metabolism (glycerol, dextrose, and cholesterol) and hypoxia. Significant bactericidal activity against Mtb was observed regardless of carbon source. Extracts from A. afra showed the highest bactericidal activity against Mtb for tested carbon sources, and A. annua bactericidal activity was greatest against Mtb in minimal media with glycerol. A. annua and A. afra. extracts were bactericidal against Mtb under hypoxic conditions. Growth was halted and viability diminished several logs-fold under hypoxic conditions in the presence of each extract. Transcriptomic analysis revealed that A. afra exerts different effects on Mtb than artemisinin, indicative of phytochemicals in A. afra with unique modes of action. Biochemometric analysis of A.

Abstract: Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(IR,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol. Its empirical formula is C21H30O2 and its molecular weight is 314.46. CBD is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. CBD is a white to pale yellow crystalline solid which is insoluble in water and soluble in organic solvents. The present invention encompasses the surprising recognition that certain CBD preparations which are prepared from a botanical origin are more effective in treating diseases or disorders than preparations of CBD which are synthetic or purified to the extent no other impurities in the form of other cannabinoids are present. Prior CBD compositions have been prepared such that no psychoactive components, e.g., tetrahydrocannabinol (THC), remain in the final CBD preparation. Surprisingly, the absence of such minor impurities reduces the efficacy of CBD treatment.

Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the prevention or treatment of hyperammonemia in an individual.

Abstract: A method of treating Sar-cov-2 re-infection in a subject, a method of reducing side effects in a subject suffering from side effects of Covid-19 vaccination, a method of reducing apoptosis of immune cells or gut cells caused by a Sar-cov-2 spike protein in a subject, a method of reducing necrosis of immune cells or gut cells caused by a Sar-cov-2 spike protein in a subject, a method of increasing CD26 level in immune cells in a subject infected with Sar-cov-2, and a method of decreasing cell adhesion molecule level in immune cells in a subject infected with Sar-cov-2 are disclosed. Each method comprises administering an effective amount of a pharmaceutical composition comprising artemisinin or artesunate to said subject. A method of making an anti-Sar-cov-2 compound by making and testing derivatives artemisinin or artesunate is disclosed.

Abstract: The present invention relates to vitamin C preparations which enhance absorption of vitamin C into cells and prolong the retention of vitamin C within the blood plasma and tissue of mammals, such as humans. The vitamin C preparations of the present invention include lipophilic molecules which improve the absorption of vitamin C resulting in higher plasma and cellular levels.

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A method is provided for lowering blood sugar in a subject in need thereof by administering a dipeptidyl peptidase-4 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the dipeptidyl peptidase-4 inhibitor pharmaceutical composition. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes saxagliptin, sitagliptin, linagliptin, alogliptin, or a pharmaceutically acceptable salt thereof. In some embodiments, the dipeptidyl peptidase-4 inhibitor pharmaceutical composition includes (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile or a pharmaceutically acceptable salt thereof.

Abstract: A pharmaceutical composition contains Indomethacin. In particular, the composition is a suppository containing a hard fat as a base material.

Abstract: The present invention relates to methods and pharmaceutical compositions for treating heart failure in a pediatric human patient comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril and valsartan in a pharmaceutically acceptable form and in a 1:1 molar ratio.

Abstract: The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.

Abstract: Provided herein are cocrystalline forms including BTK-I useful in the treatment and prevention of diseases which can be treated with a BTK inhibitor, including BTK-associated diseases and disorders, characterizations, and methods of making these cocrystalline forms.

Abstract: Aspects of the present disclosure are directed to methods of treating an interstitial lung disease (ILD) in a patient, comprising administering a pharmaceutical treatment that is useful in the therapy of an ILD; and, in conjunction with the administration of the pharmaceutical treatment, engaging in a digital therapeutic program that delivers cognitive behavioural therapy for the treatment of anxiety which the patient identifies as leading to possible exacerbations of the symptoms of the ILD. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).

Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen.

Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-TOR inhibitors, PI3k inhibitors, PARP inhibitors, BCL-2 inhibitors, and MCL-1 inhibitors.

Abstract: The nanoemulsion (NE) formulation for treating diabetes mellitus (DM) includes pioglitazone (PGZ) and a nanoemulsion formulated with Nigella sativa oil (NSO). The (PGZ)-loaded nanoemulsion formulation can achieve a significant reduction in blood glucose levels when compared to commercially available pioglitazone formulations. Thus, it is believed that Nigella sativa oil (NSO) potentiates the hypoglycemic effect of pioglitazone (PGZ). In addition, the (PGZ)-loaded nanoemulsion formulation can be stably stored for a period of at least three months.

Abstract: The present invention relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one for treating diabetes. According to the present invention, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one of the present invention alleviates clinical symptoms of diabetes, reduces blood sugar, reduces blood glucose concentrations and insulin-resistance and reduces liver and kidney damages in an animal model of insulin-resistant diabetes, and thus can be effectively used for preventing or treating diabetes, especially insulin-resistant diabetes.

Abstract: A method of screening for a drug combination for treating colorectal carcinoma, the screened drug combination and its related application are provided. The drug combination includes at least three selected from Regorafenib, Gemcitabine, Cetuximab and 5-Fluorouracil. With the method of the disclosure, the best and novel drug combination can be selected from the existing clinical drugs, the technical effect of rapidly screening for a drug combination can be achieved, and the screened combination drug has an excellent therapeutic effect.

Abstract: Disclosed are compounds of Formula (I): pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.

Abstract: A composition and a preparation method therefor, the composition including an active ingredient and a stabilizer, wherein the stabilizer includes an ionic surfactant and a spatial stabilizer. The composition has advantages, such as a high dissolution rate, a fast dissolution speed, a high particle size stability and a high bioavailability, as well as a small tablet weight, granule weight or preparation volume. The preparation method has advantages such as simple operation and being environmentally friendly.

Abstract: The present invention provides a method for treating patients with cognitive dysfunction complicating HIV-associated CM with lenalidomide. Patients with HIV-associated CM develop IRIS, some of which develop cognitive dysfunction. The patients with HIV-associated CM-IRIS are diagnosed as having cognitive dysfunction by Chinese version of the Montreal Cognitive Assessment (MoCA) and International HIV Dementia Scale (IHDS). After the treatment with lenalidomide, the MoCA score and IHDS score of the patients are improved significantly, and the leukocyte, proteins, albumin, IgG and inflammatory cytokines (growth-related oncogene, interleukin [IL]-10, granulocyte-colony stimulating factor, IL-6, IL-8, complement factor H, tumor necrosis factor-?, and ?2 macroglobulin) in cerebrospinal fluid are greatly reduced.

Abstract: The present invention provides a method for promoting functional cure of AIDS by reducing HIV reservoir with lenalidomide, the method including administering a therapeutically effective amount of lenalidomide to a patient. Also provided is a method for reducing intracellular P24 and cell-related HIV RNA in PBMCs derived from HIV patients in vitro with lenalidomide, including orally administering lenalidomide at 25 mg/d at days 1 to 21 in a 28-day cycle, and continuing ART for 48 weeks. Further provided is a method for inhibiting latent activator-induced activation of latent HIV cell line U1 with lenalidomide, including orally administering lenalidomide at 25 mg/d at days 1 to 21 in a 28-day cycle, and continuing ART for 48 weeks.

Abstract: The present invention relates to a pharmaceutical composition comprising a sphingosine-1-phosphate receptor agonist with a controlled particle size and, more specifically, to a pharmaceutical composition comprising: as an active ingredient, 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazole-5-ylmethoxy)-3,4-dihydro-naphthalene-2-ylmethyl]-piperidine-4-carboxylic acid of chemical formula 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the particle size d(0.9) of the active ingredient is 60 ?m or less.

Abstract: Methods of treating progeria, including HGPS and PL, are provided. In some embodiments, the method comprises administering to a subject having progeria a formulation of lonafarnib.

Abstract: This invention relates generally to neurodegenerative diseases and conditions (e.g., Alzheimer's disease) characterized with aberrant CD44 and FERM protein interaction. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions comprising agents capable of inhibiting CD44 and FERM protein interaction.

Abstract: A method for inhibiting the metastasis of triple-negative breast cancer, which includes administering to a subject in need thereof a pharmaceutical composition containing rosoxacin or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.

Abstract: Provided is a method of treating a neurological or psychiatric disease or disorder in a patient in need thereof, comprising: administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to the patient in need thereof, the patient also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor.

Abstract: Described herein are methods for administering a chemotherapeutic agent to a patient in need thereof. Such methods may treat, prevent, or ameliorate tumor CIN associated with administration of a chemotherapeutic agent, resulting in therapeutic resistance, tumor progression and death also described are kits and compositions useful to implement the methods.

Abstract: Disclosed are methods for preventing, delaying or reversing age-associated inflammation, by administering to a patient in need thereof a therapeutically effective amount of at least one long interspersed nuclear element 1 (LINE-1, L1) endonuclease inhibitor (L1 EN inhibitor), either alone or in combination with at least one additional therapeutic agent. Effectiveness of the methods can be measured via biomarkers and/or by a decrease in symptoms compared to those symptoms before administration of the L1 EN inhibitor. Specific chemical structures of the L1 EN inhibitors are identified and shown herein.

Abstract: The present invention provides an agent for promoting lipid reduction, containing IPO and/or a salt thereof as an active ingredient.

Abstract: The present invention relates to: a pharmaceutical composition for antipyresis, anti-inflammatory efficacy, anti-viral efficacy and treatment or prevention of COVID-19 infection, the pharmaceutical composition containing artesunate or a salt thereof, and pyronaridine or a salt thereof; and a method using same. Also, the pharmaceutical composition exhibits and excellent antipyretic effect even with a small dosage regimen, has few adverse events, and has an excellent effect in treating and preventing upper respiratory tract infections, COVID-19 and influenza.

Abstract: An aerosol-forming substrate and an aerosol generation system are provided. The aerosol-forming substrate includes yohimbine or a pharmaceutically acceptable salt of yohimbine or yohimbine hydrate. Based on a total mass of the aerosol-forming substrate, a mass percent of the yohimbine or the pharmaceutically acceptable salt of the yohimbine or the yohimbine hydrate is in a range of 0.1%-10%, preferably 0.1%-8%, further preferably 0.1%-6%, further preferably 0.1%-5%, further preferably 0.5%-5%, further preferably 1%-5%, and further preferably 2%-5%. In the aerosol-forming substrate containing yohimbine or a pharmaceutically acceptable salt of yohimbine or yohimbine hydrate provided in this application, no carbonization occurs after repeated heating by using an electronic vaporization device, and a conversion rate of yohimbine is relatively high, so that a content of yohimbine is close to a dosage through oral administration or injection in current clinical trials, thereby guaranteeing safety.

Abstract: The present invention is directed to compounds which have been identified, as inhibitors of the expression of CDR1 (Cdr1p) and/or CDR2 (Cdr2p), both ABC-type plasma, membrane transporters, which are major contributor to antifungal therapy resistance. These compounds may be used in the treatment of fungal infections, especially Candida infections, either alone or in combination with azole antifungal agents such as fluconazole, itraconazole, miconazole, clotrimazole and the like. Often the inhibitor compounds described herein are useful for reversing the antifungal therapy resistance exhibited by the overexpression of CDR1 and/or CDR2 in strains of fungi, especially including Candida spp. Combination therapy and compositions for treating fungal infections, especially including azole resistant fungal infections represent important embodiments of the present invention.

Abstract: Provided herein are safe and effective dosing regimens for mitapivat and/or pharmaceutically acceptable salts thereof.

Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

Abstract: Described herein are chemoembolization compositions comprising an anti-cancer drug, methods of making, and their use in treating cancer, such as liver cancer.

Abstract: Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with PKC and MEK.

Abstract: Described are methods of use of compounds that inhibit PIF-mediated substrate binding by PDK1, which are useful as inhibitors of cancer growth or proliferation that is RSK2-dependent or AKT-independent. Also described are compositions of such compounds for use in such methods of treating cancer.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 ?g/kg/day.

Abstract: The current disclosure provides novel therapeutic methods for treating SCLC and other neuroendocrine cancers by evaluating the biomarker SLFN 11. Aspects of the disclosure relate to a method for treating a subject with small cell lung cancer (SCLC) or with a neuroendocrine cancer, the method comprising administering one or more therapeutics to a subject that has had been evaluated for SLFN 11 expression in a biological sample from the subject; wherein the one or more therapeutics comprise lurbinectedin.